论文部分内容阅读
美国FDA于2012年3月6日批准由Discovery Laboratories Inc.公司生产的Surfaxin(通用名为lucinactant)用于治疗早产儿呼吸窘迫综合征(RDS)。早产儿发生呼吸窘迫综合征的原因是其肺部无法产生足够的表面活性剂(surfactants)。表面活性剂是一种
US FDA approved Surfaxin (commonly known as lucinactant) from Discovery Laboratories Inc. on March 6, 2012 for the treatment of respiratory distress syndrome (RDS) in preterm infants. The cause of respiratory distress syndrome in preterm infants is the inability of the lungs to produce enough surfactant. Surfactants are one kind